The present studies mapped the protein kinase A (PKA) phosphorylation site of G␣ 13 and studied the consequences of its phosphorylation. Initial experiments using purified human G␣ 13 and the PKA catalytic subunit established that PKA directly phosphorylates G␣ 13 . The location of this phosphorylation site was next investigated with a new synthetic peptide (G 13 SRI pep ) containing the PKA consensus sequence (Arg-Arg-ProThr 203 ) within the switch I region of G␣ 13 . G 13 SRI pep produced a dose-dependent inhibition of PKA-mediated G␣ 13 phosphorylation. On the other hand, the Thr-phosphorylated derivative of G 13 SRI pep possessed no inhibitory activity, suggesting that G␣ 13 Thr 203 may represent the phosphorylation site. Confirmation of this notion was obtained by showing that the G␣ 13 -T203A mutant (in COS-7 cells) could not be phosphorylated by PKA. Additional studies using co-elution affinity chromatography and co-immunoprecipitation demonstrated that G␣ 13 phosphorylation stabilized coupling of G␣ 13 with platelet thromboxane A 2 receptors but destabilized coupling of G␣ 13 to its ␤␥ subunits. In order to determine the functional consequences of this phosphorylation on G␣ 13 signaling, activation of the Rho pathway was investigated. Specifically, Chinese hamster ovary cells overexpressing human G␣ 13 wild type (G␣ 13 -WT) or G␣ 13 -T203A mutant were generated and assayed for Rho activation. It was found that 8-bromo-cyclic AMP caused a significant decrease (50%; p < 0.002) of Rho activation in G␣ 13 wild type cells but produced no change of basal Rho activation levels in the mutant (p > 0.4). These results therefore suggest that PKA blocks Rho activation by phosphorylation of G␣ 13 Thr 203 .
transmembrane receptors, evidence has been provided that phosphorylation of specific sites can serve to alter receptor-G protein coupling, initiate receptor internalization, and ultimately modulate cross-membrane receptor signaling (1) . Whereas such effects of receptor phosphorylation have been well documented, considerably less is known regarding the prevalence or the possible signaling consequences of G protein phosphorylation (2) (3) (4) (5) (6) . Nevertheless, several reports have provided evidence that G protein phosphorylation can alter heterotrimer complex formation and downstream signaling events. Specifically, Kozasa and Gilman (4) demonstrated that in vitro phosphorylation of G␣ 12 and G␣ z by PKC 1 results in conformational changes that inhibit interaction of the G␣ and G␤␥ subunits. A similar PKC-mediated phosphorylation effect on G␣-G␤␥ interaction was observed by Fields and Casey (3) for G␣ z and by Murthy et al. (6) for G␣ i1/2 . Offermanns et al. demonstrated that a PKC-dependent phosphorylation of G␣ 12 and G␣ 13 occurred when human platelets were activated by thrombin, the TXA 2 mimetic U46619, or the phorbol ester phorbol 12-myristate 13-acetate (PMA) (7) . Collectively, the above results therefore suggest that different G␣ subunits can indeed serve as substrates for PKC. Whereas the functional consequences of such phosphorylation remain largely unknown, the strategic position of G proteins in the signaling cascade suggests that phosphorylation-mediated changes in G protein conformation or activity could serve as a significant regulatory point in the signaling process. In this connection, we recently provided evidence that TXA 2 receptor-coupled G␣ 13 is phosphorylated through a PKA-mediated process (8) . These results represented the first demonstration that a platelet G␣ subunit is phosphorylated by cAMP-dependent kinase and provided a possible explanation for the high sensitivity of TXA 2 receptor signaling to increased cAMP levels. The present studies extend these findings by characterizing the specific PKA phosphorylation site in G␣ 13 and identifying the molecular and functional consequences of this phosphorylation. Our results demonstrate that PKA phosphorylates G␣ 13 at Thr 203 , which is situated within the functionally important switch I region of the G␣ subunit (9 -14) . This phosphorylation results in stabilization of G␣ 13 coupling to TXA 2 receptors and destabilization of G␣ 13 coupling to its ␤␥ subunits. Separate experiments also provided evidence that a functional consequence of this phosphorylation is decreased basal Rho activation levels. Thus, PKA-mediated G␣ 13 Thr 203 phosphorylation appears to repre-sent a novel mechanism for the regulation of signaling through the G␣ 13 pathway.
MATERIALS AND METHODS
Reagents-G 13 SRI pep (CLLARRPTKGIHEY) and G 13 SRI pep P (CLLARRPpTKGIHEY (where pT represents phosphothreonine)) peptides were synthesized by Multiple Peptide Systems (San Diego, CA). An N-terminal cysteine was added to each peptide to aid in coupling to carrier protein for future antibody production. Outdated human platelet units were obtained from Heartland Blood Centers (Aurora, IL). G418 was obtained from Calbiochem; PKA cat (protein kinase A, catalytic subunit, bovine heart), protein A-Sepharose, aprotinin, leupeptin, coumeric acid, luminol, 8-Br-cAMP, NaF, and CHAPS were obtained from Sigma; [␥-32 P]ATP (4,500 Ci/mmol) was purchased from ICN Biochemicals, Inc.; G 13 -N, Myc, G␣ 12 , and G␤ common IgG and Rho A polyclonal antibodies were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA); rabbit polyclonal anti-peptide antibodies to TXA 2 receptor (P 2 Ab) and G␣ q (QL Ab) were prepared as previously described (15) ; the Wizard Plus Midiprep DNA Purification kit was from Promega (Madison, WI); LipofectAMINE Plus and LipofectAMINE 2000 were purchased from Invitrogen; the QuikChange site-directed mutagenesis kit was from Stratagene (La Jolla, CA); horseradish peroxidaseconjugated goat anti-rabbit IgG (H ϩ L) was from Bio-Rad; the BCA protein assay kit was from Pierce; and the Rho activation assay kit was from Upstate Biotechnology, Inc. (Lake Placid, NY). Primers (T203A-DS, 5Ј-GGA TGC CTT TGG CGG GTC TTC TGG CAA GCA GAA TAT CTT G-3Ј; T203A-US, 5Ј-GCC AGA AGA CCC GCC AAA GGC ATC CAT GAA TAC GAC TTT G-3Ј) were from Integrated DNA Technologies, Inc. (Coralville, IA).
In Vitro Phosphorylation of Purified G␣ 13 -G␣ 13 (16) was purified from Sf9 cells, as previously described (17) . For phosphorylation of purified G␣ subunits, 5 pmol of G␣ subunit was added to 20 mM [␥-32 P]ATP (4,500 Ci/mmol), PKA cat (protein kinase A, catalytic subunit (50 ng; 60 units) or PKA vehicle (100 mM NaCl, 20 mM MES, pH 6.5, 30 mM ␤-mercaptoethanol, 100 mM EDTA, 50% ethylene glycol) in phosphorylation buffer (25 mM Tris-HCl, pH 7.5, 5 mM MgCl 2 , 125 mM CaCl 2 , 1 mM dithiothreitol) in a total reaction volume of 115 l, and the mixture was incubated for 30 min at 30°C. The reaction was terminated by adding Laemmli (18) sample buffer (62.5 mM Tris-HCl, pH 6.5, 3% SDS, 10% glycerol). Proteins were separated by SDS-PAGE and were visualized by silver staining (19) followed by autoradiography.
Cell Culture and Transfection-COS-7 cells and CHO cells were maintained in Dulbecco's modified Eagle's medium containing 4.5 g/liter glucose, 10% fetal bovine serum, 100 units/ml penicillin, 100 g/ml streptomycin, and 0.25 g/ml amphotericin B. COS-7 cells were transiently transfected when the cells were 80 -90% confluent in 100-mm culture dishes. The medium was replaced with serum-free Dulbecco's modified Eagle's medium, and the cells were transfected using the LipofectAMINE Plus method (Invitrogen) according to the manufacturer's protocol, using 10 g of DNA and 20 l of LipofectAMINE per transfection. After 3 h at 37°C, the medium was supplemented with 1 volume of 20% fetal bovine serum, Dulbecco's modified Eagle's medium. Experiments were performed 48 h after transfection. Transient transfection of COS-7 cells with cDNAs for G␣ 13, G␤ 1 , and Myc-tagged G␥ 2 subunits was performed using LipofectAMINE 2000 reagent, according to the manufacturer's instructions. Transfections in CHO cells with human G␣ 13 wild type (G␣ 13 -WT) or G␣ 13 -T203A mutant plasmids were performed as described above. After 3 days of transfection, G418 (500 g/ml) was added for selection. After 3-5 weeks, the stable cell lines were established and confirmed by Western blot.
Immunoprecipitation and Phosphorylation of G␣ 13 -The transfected cells were washed three times with cold PBS and were harvested with lysis buffer (50 mM Hepes, pH 7.4, 10 mM MgCl 2 , 1 mM EDTA, 100 mM NaCl, 1% Triton X-100, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 20 g/ml aprotinin, 20 g/ml leupeptin). The lysates were centrifuged to remove insoluble material, and the protein concentration of the supernatant was measured using the BCA protein assay method. The protein concentration of each lysate was adjusted to be equal within an experiment and was typically 0.50 -2.0 mg/ml. Aliquots of 0.6 ml were incubated overnight at 4°C with 10 g/ml G␣ 13 antibody and were subsequently incubated with protein A-Sepharose beads (55 l of a 10% (w/v) suspension) for 4 h at 4°C. The immune complexed beads were washed once with lysis buffer and were supplemented with resuspension buffer (50 mM Hepes, pH 7.5, 10 mM MgCl 2 , 1 mM EGTA, 0.014% Tween 20, 1 mM dithiothreitol). 85 l of protein-bound beads were then incubated with 50 M [␥-
32 P]ATP, 150 ng of PKA, 1 mM cAMP, and the indicated concentration of blocking peptide in a total volume of 125 l.
The mixture was incubated for 30 min at 30°C, after which time the beads were pelleted by centrifugation and washed three times with resuspension buffer. The beads were then suspended in Laemmli sample buffer plus resuspension buffer, and immune complexes were eluted by boiling. The eluted proteins were subjected to SDS-PAGE, silver staining, and autoradiography. Phosphorylated proteins on autoradiograms were quantified using a densitometer (Protein Databases, Inc., Huntington Station, NY), and values were normalized for the amount of silver-stained protein on the gel.
DNA Constructs and Site-directed Mutagenesis-G␣ 13 was cloned from a human adenocarcinoma LoVo cell line and was subcloned into a pcDNA3 vector. The G␣ 13 mutation with the substitution of Ala for Thr 203 was performed using the Stratagene QuikChange site-directed mutagenesis kit according to the manufacturer's protocol. The final mutant was verified by DNA sequencing.
Ligand Affinity Chromatography-12 units of outdated human platelets were pooled and incubated with 3 mM aspirin for 45 min. Solubilized platelet membranes were then prepared as previously described (8) , yielding a typical protein concentration of 4.5 mg/ml. Solubilized membranes were phosphorylated and purified by ligand affinity chromatography, as described (8) . Briefly, solubilized proteins were incubated with 1 mM 8-Br-cAMP or vehicle (H 2 O), 100 l of ATP, 60 mM CaCl 2 , and incubation medium (45 mM histidine HCl, 50 mM KH 2 PO 4 , 20 mM NaF, 120 mM KCl, pH 7.4) for 30 min at 30°C. The phosphorylated samples were supplemented with 500 mM KCl, 0.5 mg/ml asolectin, 20% glycerol, 0.2 mM EGTA, 10 mM CHAPS and were incubated on the ligand affinity columns overnight at 4°C. Unbound proteins were washed with buffer D (20 mM Tris base, 10 mM CHAPS, 20% glycerol, 500 mM KCl, 0.2 mM EGTA, 0.5 mg/ml asolectin, pH 7.4) supplemented with 20 mM NaF and 2 mM orthovanadate. TXA 2 receptor-G protein complexes were eluted from the column with the TXA 2 antagonist BM13.177 in buffer D at a flow rate of 0.125 ml/min. A 3-ml elution fraction was collected, dialyzed in 10 mM NH 4 HCO 3 , and then lyophilized. Proteins were reconstituted into 150 l of H 2 O and were subjected to SDS-PAGE.
Pull-down Assay for GTP-Rho-Rho activation was determined as previously described (20) . CHO-G␣ 13 -WT and CHO-G␣ 13 -T203A mutant cells were seeded on six-well plates, grown to 80% confluence, and serum-starved for 24 h. Following treatment with 8-Br-cAMP (1 mM) at 37°C for 15 min, the cells were washed once with PBS and harvested with 300 l of lysis buffer (50 mM Tris-HCl, pH 7.5 containing 100 mM NaCl, 1 mM EDTA, 5 mM MgCl 2 , 10% glycerol, 50 mM NaF, 1 mM Na 3 VO 4, 1 mM dithiothreitol, 50 g/ml phenylmethylsulfonyl fluoride, 10 g/ml each of leupeptin and pepstatin, and 0.2% Nonidet P-40). The cell lysates were clarified by centrifugation at 15,000 ϫ g for 1 min and incubated with 20 g of glutathione S-transferase-Rho binding domain fusion protein conjugated with glutathione beads at 4°C for 1 h. The beads were washed three times with lysis buffer and subjected to SDS-PAGE on a 12% gel. Bound RhoA was detected by Western blot using a polyclonal antibody against RhoA.
Statistical Analysis-Data were analyzed according to the analysis of variance using Dunnett's multiple comparison post-test or Student's t test, as indicated, using GraphPad PRISM statistical software (San Diego, CA). Statistical significance is defined as p Ͻ 0.05, p Ͻ 0.01, or p Ͻ 0.002, as indicated.
RESULTS
In Vitro PKA phosphorylation of Purified G␣ 13 -Whereas we previously demonstrated that cAMP induces phosphorylation of TXA 2 receptor-coupled G␣ 13 in human platelets (8), these results did not determine whether the observed phosphorylation is directly mediated by PKA or whether additional kinases are involved. In order to address this question, additional studies were performed using human G␣ 13 purified from Sf9 cells (16) with [␥-
32 P]ATP in the presence or absence of the PKA catalytic subunit (PKA cat ). Electrophoretic separation and silver staining of these samples revealed the presence of a single protein at 44 kDa corresponding to G␣ 13 (Fig. 1a , lanes 1 and 2) but no such band in the presence of PKA alone (Fig. 1a, lane 3) . Analysis of this gel by autoradiography revealed substantial phosphorylation of G␣ 13 (at 44 kDa) when PKA is added (Fig.  1b , lane 1) but no phosphorylation (Fig. 1b, lane 2) in the absence of PKA. These experiments therefore establish that PKA alone is sufficient to phosphorylate G␣ 13 . The specificity of this G␣ 13 phosphorylation was examined in parallel experi-ments by assaying a separate platelet G protein, G␣ i (purified from Sf9 cells as previously described) (17) . Fig. 1a illustrates a single protein band (lanes 4 and 5) corresponding to G␣ i . However, it can also be seen (Fig. 1b, lanes 4 and 5) that no phosphorylation of G␣ i was observed in either the presence or the absence of PKA. Collectively, these results demonstrate that PKA directly phosphorylates G␣ 13 and that this reaction does not require intermediate kinases or other co-factors.
Inhibition of G␣ 13 Phosphorylation by a G␣ 13 Peptide Containing a PKA Consensus Sequence-A 14-amino acid synthetic peptide (G 13 SRI pep ) corresponding to the specific G␣ 13 amino acid sequence Leu 197 -Tyr 209 was initially used to locate the PKA phosphorylation site of G␣ 13 . This amino acid region was selected because analysis of the primary structure of the G␣ 13 subunit revealed only one PKA consensus sequence represented by Arg-Arg-Pro-Thr 203 . On this basis, G 13 SRI pep , which encompasses this region, was used to probe the Leu 197 -Tyr 209 region for potential phosphorylation. Thus, it was reasoned that PKA-mediated phosphorylation of G␣ 13 would be blocked or reduced by a competing peptide substrate (G 13 SRI pep ) containing an amino acid sequence that is identical to that contained within G␣ 13 . In these experiments, human wild type G␣ 13 was immunoprecipitated from transiently transfected COS-7 cell using protein A-Sepharose beads coupled to an anti-peptide antibody directed against the N terminus of G␣ 13 (G 13 -N IgG). The ␣ subunit-antibody-bead complex was then incubated with PKA cat and [␥-32 P]ATP in the presence or absence of G 13 SRI pep . Following incubation, the proteins were eluted from the beads and were subjected to gel electrophoresis and autoradiography. It can be seen that the efficiency of immunoprecipitation was comparable for each G␣ 13 -transfected COS-7 cell sample (Fig. 2a, lanes 1-6) . It can also be seen that PKA induced a substantial G␣ 13 phosphorylation (Fig. 2b,  lane 1) . Furthermore, upon the addition of G 13 SRI pep , there was a dramatic dose-dependent inhibition of this PKA-mediated effect (Fig. 2b, lanes 2-5) . Quantitation of this peptide inhibition is illustrated in Fig. 2c , where it can be seen that G␣ 13 phosphorylation was significantly blocked at a peptide concentration of as little as 50 M, and was completely inhibited at a peptide concentration of 500 M. Fig. 2a, lanes 7 and 8, demonstrate that the vector-transfected COS-7 cells do not reveal detectable amounts of G␣ 13 under these conditions, and consistent with this finding, there was no observed PKA-induced phosphorylation in the 44-kDa region of the immunoprecipitated protein samples (Fig. 2b, lanes 7 and 8) . These findings using transfected COS-7 cells therefore confirm our previous results in platelets showing PKA-mediated phosphorylation of G␣ 13 and suggest that the PKA phosphorylation site of G␣ 13 is contained within the Leu 197 -Tyr 209 sequence. However, since it is possible that the ability of G 13 SRI pep to block phosphorylation was due to a nonspecific peptide effect, a control peptide was evaluated in subsequent experiments. Specifically, it was reasoned that the most appropriate control would employ a peptide with an amino acid sequence identical to that of G 13 SRI pep , the only difference being substitution of a phosphorylated Thr in the peptide sequence. Thus, the phosphorylated peptide should serve as a poor substrate for PKA. On this basis, G 13 SRI pep P was synthesized and tested for its ability to affect PKA-mediated phosphorylation under the same experimental conditions as those used for G 13 SRI pep . As can be seen in Fig 3a, lanes 1-4 , equal amounts of G␣ 13 protein were immunoprecipitated under each experimental condition. It can also be seen (Fig. 3b, lane 1) that PKA addition again resulted in substantial G␣ 13 phosphorylation. However, in contrast to the effects of G 13 SRI pep , the addition of G 13 SRI pep P was completely ineffective in blocking this PKA-mediated phosphorylation (Fig. 3b, lanes 2 and 3) , even at a concentration (500 M) that resulted in complete inhibition by G 13 SRI pep . The quantitative analysis of these phosphorylation profiles is illustrated in Fig. 3c . Since G␣ 13 contains only a single PKA consensus sequence within Leu 197 -Tyr 209 , these findings therefore suggest 1) that G 13 SRI pep specifically acts to block PKA-induced phosphorylation of G␣ 13 ; 2) that the location of the PKA phosphorylation site is contained within the Leu 197 -Tyr 209 sequence of G␣ 13 ; and 3) that Thr 203 serves as the phosphorylation site within this sequence.
PKA Does Not Phosphorylate G␣ 13 -T203A Mutant Protein-In order to provide independent confirmation that Thr 203 is in fact the residue phosphorylated by PKA, a mutant G␣ 13 (G␣ 13 -T203A) was produced in which Thr 203 was changed to Ala by site-directed mutagenesis. In these experiments, the G␣ 13 -T203A mutant (or wild type G␣ 13 ) was immunoprecipitated from transiently transfected COS-7 cells using the G 13 -N antibody, and the ␣ subunit-antibody-bead complex was subjected to phosphorylation, as described earlier. It can be seen (Fig. 4a, lanes 1-4) (Fig. 4b) . In this regard, some experiments revealed a minor phosphorylation in the mutant with or without PKA. However, this apparent phosphorylation was not found to be significantly different from vector control, and no detectable phosphorylation was observed in the mutant autoradiogram (Fig. 4b, lanes 3 and 4) . The complete absence of PKA-induced phosphorylation in the T203A mutant, in combination with the previous results, therefore provides evidence that PKA phosphorylates a single site at Thr 203 contained within switch I region of G␣ 13 .
Binding of ␤␥ to Wild Type G␣ 13 and G␣ 13 -T203A Mutant Protein-The next series of experiments investigated the molecular consequences of this PKA-mediated Thr 203 phosphorylation. Because phosphorylation is known to alter protein conformation and function, it is possible that Thr 203 phosphorylation may change the conformational or chemical characteristics of G␣ 13 and thereby alter its normal function in the receptor-coupled signaling process. Indeed, this possibility might be anticipated for two reasons: 1) Thr 203 resides within switch I region of the G␣ 13 subunit, and 2) the switch I region is considered important for modulating activation of the ␣ subunit and for regulating its affinity for the ␤␥ subunits (16) . Based on these considerations, we examined whether PKA phosphorylation of the switch I region Thr 203 residue affects the stability of the G␣␤␥ 13 heterotrimeric complex.
In these studies, COS-7 cells were transfected with either wild type or mutant G␣ 13 (G␣ 13 -T203A) as well as with ␤ and Myc-tagged ␥ 2 . The ␤␥ subunits were then immunoprecipitated with anti-Myc antibody. It can be seen that co-transfection of ␤ and Myc-tagged ␥ 2 cDNAs alone (without G␣ 13 ) showed no G␣ 13 protein in either the lysate or the immunoprecipitate (Fig.  5, row a, lane 3, and row b, lane 3) . As expected, G␣ 13 was immunoprecipitated ( Fig. 5 row a, lane 2) and present in the lysate (Fig. 5, row b, lane 2) when the cells were co-transfected with ␤, Myc-tagged ␥ 2 cDNAs, and wild type G␣ 13 . On the other hand, no such G␣ 13 immunoprecipitation was observed (Fig. 5,  row a, lane 1) when the co-transfection was done with G␣ 13 -T203A mutant. Furthermore, Western blotting of total cell lysates demonstrated that both constructs of G␣ 13 were expressed at the same levels (Fig. 5, row b, lanes 1 and 2) , suggesting that the inability of mutated G␣ 13 to complex with ␤ 1 ␥ 2 was not due to insufficient expression. These findings therefore suggest that mutation of G␣ 13 at Thr 203 disrupts heterotrimer stability.
Ligand Affinity Co-purification of TXA 2 Receptor-G Protein Complexes-The next series of experiments extended the above finding and investigated possible consequences of G␣ 13 Thr 203 phosphorylation on stability of the receptor-G␣ 13 complex. To this end, affinity purification of the receptor-G protein complex was employed. This technique has previously been used to co-purify native TXA 2 receptors with their associated G␣ proteins (21, 22) and was used to demonstrate PKA phosphorylation of TXA 2 receptor-coupled G␣ 13 (8) . In the present experiments, solubilized platelet membranes were prepared and incubated in the presence or absence of 1 mM 8-Br-cAMP plus [␥-
32 P]ATP. The TXA 2 receptor-G protein complexes were then purified by affinity chromatography (8) , and the column eluate was assayed for TXA 2 receptor, G␣ 13 , G␣ q , and ␤ subunits by immunoblotting. It can be seen that in the absence of 8-BrcAMP (Fig. 6a, lane 1 receptor elute fractions yielded positive immunoreactivity for the G␣ 13 , G␣ q , and G␤ subunits. It can also be seen, however, that 8-Br-cAMP treatment produced a significant shift in this elution profile (i.e. a substantial increase in co-eluted G␣ 13 and a substantial decrease in co-eluted G␤) (Fig. 6a, lane 2) . On the other hand, 8-Br-cAMP treatment produced no change in the amounts of either G␣ q or TXA 2 receptor (Fig. 6a, lanes 1 and 2) . Quantitation of these results is illustrated in Fig. 6b .
The ability of 8-Br-cAMP to cause such a selective effect on the G 13 heterotrimeric complex is consistent with previous results, which have shown that PKA is capable of phosphorylating G␣ 13 (8) but incapable of phosphorylating either G␣ q (23) or platelet TXA 2 receptors.
2 Furthermore, since it is known that co-elution of complexed proteins is proportional to the affinity between these proteins, the observed shifts in the elution profiles for both G␣ 13 and ␤ subunits suggest that PKAmediated Thr 203 phosphorylation of G␣ 13 has two separate effects on G␣ 13 . First, this phosphorylation appears to destabilize its association with G␤␥ subunits, resulting in ␤␥ dissociation. This finding is consistent with the results in Fig. 5 using Myc-tagged ␥ 2 . Second, Thr 203 phosphorylation appears to stabilize the association between TXA 2 receptors and G␣ 13 . Thus, PKA-mediated phosphorylation within the switch I region of G␣ 13 appears to impact the interaction of this G␣ subunit with each of its protein partners.
PKA-mediated Inhibition of Rho Activation-Since G␣ 13 is known to signal through the Rho pathway (16, 24 -27) , the final series of experiments investigated the effects of G␣ 13 Thr 203 phosphorylation on the basal Rho activation state. In these studies, CHO cell lines overexpressing human G␣ 13 -wild type (G␣ 13 -WT) or G␣ 13 -T203A mutant (which cannot undergo PKA phosphorylation; Fig. 4) were assayed for G␣ 13 -Rho activation. Fig. 7 illustrates the fraction of activated Rho A relative to total Rho A in the cell homogenate. Using G␣ 13 -WT cells, it was found that the addition of 1 mM 8-Br-cAMP caused a substantial decrease in basal Rho activation levels (Fig. 7, lanes 1 and  2) . On the other hand, 8-Br-cAMP did not significantly decrease Rho activation in the G␣ 13 -T203A mutant (Fig. 7, lanes  3 and 4) . The average of seven separate experiments revealed that 8-Br-cAMP caused a 50 Ϯ 14% inhibition (p Ͻ 0.002) in the G␣ 13 -WT cells but had no significant effect (5 Ϯ 13%; p Ͼ 0.4) in the mutant cells. These results therefore demonstrate that G␣ 13 T203A mutation decreases the ability of 8-Br-cAMP to block Rho activation, suggesting that G␣ 13 phosphorylation at Thr 203 interferes with the G␣ 13 signaling process.
DISCUSSION
Heterotrimeric G proteins are ubiquitously expressed across different cell lines and serve as important mediators in the initiation and maintenance of cellular function. As such, these proteins are particularly well poised to serve as targets for modulation of the separate signaling pathways. One mechanism by which the functional activity of G proteins might be regulated is through the process of phosphorylation. For example, results from studies by Aragay and Quick (5) suggested that thyrotropin-releasing hormone responses require PKC phosphorylation of G␣ 16 . This suggestion was based on the finding that mutation of the G␣ 16 PKC phosphorylation sites blocked the thyrotropin-releasing hormone-induced responses (5) . Other studies have indicated that PKC-mediated phosphorylation can down-regulate G protein activity. Specifically, Glick and Casey (28) reported that phosphorylation of G␣ z by PKC substantially reduced its activation. Furthermore, Murthy et al. reported that PKC activation leads to phosphorylation of G␣ i1 /G␣ i2 , and blocks downstream signaling events mediated through both G␣ i1 -and G␣ i2 -coupled receptors. Moreover, they suggested that phosphorylation of G␣ subunits could also indirectly affect responses mediated by ␤␥ subunits. Thus, it appears that PKC-mediated G␣ subunit phosphorylation may play a significant role in regulating G protein function and hence its downstream signaling processes.
In addition to PKC, evidence has been provided that PKA is also capable of phosphorylating G␣ subunits in vitro (29, 30) . Furthermore, we recently demonstrated that TXA 2 receptorcoupled G␣ 13 is phosphorylated by PKA in vivo (8) . The present studies extended these findings by characterizing the specific PKA phosphorylation site in G␣ 13 and identifying the molecular and functional consequences of this phosphorylation. Our initial results showed that PKA phosphorylation of G␣ 13 does not require intermediate kinases or other co-factors. Our subsequent studies using site-specific peptides and site-directed mutagenesis provided evidence that PKA phosphorylates G␣ 13 at a single site (i.e. Thr 203 contained within the switch I region of the G␣ subunit). Because this phosphorylation occurs at a conformationally sensitive site of the of the G␣ subunit, it is possible that such phosphorylation could potentially change 2 G. C. Le Breton, unpublished results. 2) and G␣ 13 -T203A mutant (lanes 3 and 4) . Effects of 8-Br-cAMP on basal Rho activation levels are shown (lanes 2 and 4) .
the structural or chemical characteristics of G␣ 13 and thereby alter its interaction with receptor-G 13 ␤␥ partners or its downstream signaling capacity. In this connection, switch I and II regions are structurally and functionally analogous to those first described in the small GTPase Ras (9), whereas the switch III region is unique to heterotrimeric G proteins. These switch regions are domains of the ␣ subunit that have been found to undergo conformational changes during G protein activation induced by GDP-GTP exchange (9 -14) . Furthermore, crystallization studies have revealed that the switch I region contains critical sites for not only binding GTP (13, 22) but also for binding the ␤␥ subunits (13) . Consequently, this region is thought to be important for modulating activation of the ␣ subunit as well as for regulating the affinity of the ␣ subunit for the ␤␥ subunits (13) .
On this basis, we next examined whether PKA phosphorylation of the switch I region Thr 203 residue of G␣ 13 affects the stability of the G␣␤␥ 13 heterotrimeric complex or the interaction of this complex with TXA 2 receptor protein. Using coelution affinity chromatography and co-immunoprecipitation, it was found that G␣ 13 phosphorylation stabilized the coupling of G␣ 13 to platelet TXA 2 receptors but destabilized the coupling of G␣ 13 to its ␤␥ subunits. Thus, phosphorylation of G␣ 13 at Thr 203 appeared to produce structural effects on the receptor-G protein heterotrimer complex.
Our final series of experiments investigated the effects of G␣ 13 Thr 203 phosphorylation on downstream signaling through Rho. It was found that 8-Br-cAMP caused a substantial reduction of the basal Rho activation state in CHO cells overexpressing wild type G␣ 13 . On the other hand, mutation of G␣ 13 Thr 203 to Ala significantly blocked the cAMP-mediated effects. Since separate experiments demonstrated that the T203A mutant is incapable of PKA-mediated phosphorylation, these results suggest that Thr 203 phosphorylation serves as a mechanism for PKA modulation of G␣ 13 downstream signaling. This finding is consistent with previous results that demonstrated cAMP-dependent inhibition of Rho activation (27) .
Based on the above considerations, we propose a model by which PKA may regulate G 13 signaling (Fig. 8) . In the resting state, an equilibrium exists between the intact receptor-G protein complex and the dissociated complex. This dissociationreassociation cycling process defines basal GTPase activity, which is normally low because most receptor-G protein exists in the complexed form. This basal activity also defines the resting activation state of the downstream effectors. On the other hand, the cycling rate can be markedly accelerated in the presence of agonist. Thus, according to the classical model (31), the agonist induces a shift in the equilibrium in favor of heterotrimer dissociation, which is characterized by increased GDP-GTP exchange on the G␣ subunit (17) . This process in turn causes a rapid dissociation of G␣ from the ␤␥ subunits, enabling both the ␣ and the ␤␥ to increase their activation of downstream effectors. Upon hydrolysis of GTP to GDP, the receptor-G␣␤␥ complex reforms and is thereby poised to undergo additional cycles of activation. On the other hand, if this cycling process is interrupted (e.g. by G␣ subunit phosphorylation), downstream effector activation could be significantly altered. Specifically, our results have shown that PKA-mediated phosphorylation of G␣ 13 at Thr 203 has two structural effects: 1) it stabilizes the G␣ 13 -G protein-coupled receptor complex, and 2) it inhibits G␣␤␥ 13 association. Whereas the mechanisms of these effects are unknown, they may involve steric considerations or phosphorylation-induced conformational changes. For example, Thr 203 is situated within the ␤␥ interacting surface of G␣ 13 . Consequently, phosphorylation of this site could prevent binding between the ␣ and ␤␥ subunits and thereby inhibit formation of the heterotrimeric complex. At the same time, Thr 203 phosphorylation may lead to conformational changes that favor stabilization of the G␣ 13 -G proteincoupled receptor binding interaction.
Regarding functional effects, stabilization of the G␣-receptor complex by phosphorylation of G␣ 13 Thr 203 would presumably lead to direct inhibition, since the G␣ subunit would be unavailable for downstream signaling. Alternatively, steric or charge-related effects of phosphorylation may also decrease binding of switch 1 region to the downstream effector (32) , again leading to inhibition. Our results showing decreased Rho activation by G␣ 13 Thr 203 phosphorylation are consistent with either of these possibilities. On the other hand, the consequences of inhibited ␤␥ reassociation by phosphorylation are less clear. For example, one might think that initial dissociation of ␤␥ would lead to downstream activation. However, this activation phase may be brief and self-limiting due to inhibition of cycling and G protein adaptation, which has recently been shown to occur in the face of persistent heterotrimeric dissociation (31 response may be biphasic, and indeed there is precedent for a transient platelet activation phase (33) caused by protein kinase G (which presumably would also phosphorylate Thr 203 ). In summary, the present findings identify a novel mechanism for modulating G protein-coupled receptor signaling. Our demonstration of PKA-mediated G␣ 13 Thr 203 phosphorylation provides evidence that a conformationally sensitive switch region of G␣ 13 can serve as a potential target for cAMP modulation. This phosphorylation appears to have both structural and functional effects in that it causes increased stability of G␣ 13 coupling to G protein-coupled receptors, decreased stability of the G␣ 13 heterotrimer complex, and decreased basal Rho activation state. Whereas the relative importance of this regulatory process is presently unknown, it is noteworthy that phosphorylated G␣ 13 exists even at basal cAMP levels (8) . This finding raises the possibility that cAMP may exhibit tonic influences on G␣ 13 signaling even at low cellular cAMP levels. Finally, sequence analysis reveals that G␣ 12 also contains a PKA consensus sequence in switch I region, whereas other G proteins (e.g. G␣ q , G␣ i , G␣ z , or G␣ s ) do not. Thus, the proposed ability of cAMP to modulate G␣ conformation/function may represent a regulatory mechanism that is unique to the ubiquitously expressed G␣ 12/13 family. Clearly, additional studies will be required to investigate this interesting possibility.
